277 related articles for article (PubMed ID: 31681616)
1. A Comparative Analysis of Individual RAS Mutations in Cancer Biology.
Muñoz-Maldonado C; Zimmer Y; Medová M
Front Oncol; 2019; 9():1088. PubMed ID: 31681616
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
3. Rare codons regulate KRas oncogenesis.
Lampson BL; Pershing NL; Prinz JA; Lacsina JR; Marzluff WF; Nicchitta CV; MacAlpine DM; Counter CM
Curr Biol; 2013 Jan; 23(1):70-5. PubMed ID: 23246410
[TBL] [Abstract][Full Text] [Related]
4. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
5. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
6. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS
Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640
[TBL] [Abstract][Full Text] [Related]
7. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
8. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations.
Hammond DE; Mageean CJ; Rusilowicz EV; Wickenden JA; Clague MJ; Prior IA
J Proteome Res; 2015 Mar; 14(3):1535-46. PubMed ID: 25599653
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
Knobbe CB; Reifenberger J; Reifenberger G
Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
[TBL] [Abstract][Full Text] [Related]
10. RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains.
Zhou Y; Gorfe AA; Hancock JF
Front Mol Biosci; 2021; 8():686338. PubMed ID: 34222339
[TBL] [Abstract][Full Text] [Related]
11. Analysis of RAS oncogene mutations in human lymphoid malignancies.
Neri A; Knowles DM; Greco A; McCormick F; Dalla-Favera R
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9268-72. PubMed ID: 3057505
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.
Parikh C; Subrahmanyam R; Ren R
Cancer Res; 2007 Aug; 67(15):7139-46. PubMed ID: 17671181
[TBL] [Abstract][Full Text] [Related]
13. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
14. RAS isoforms and mutations in cancer at a glance.
Hobbs GA; Der CJ; Rossman KL
J Cell Sci; 2016 Apr; 129(7):1287-92. PubMed ID: 26985062
[TBL] [Abstract][Full Text] [Related]
15. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
[TBL] [Abstract][Full Text] [Related]
16. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
17. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.
Farr CJ; Saiki RK; Erlich HA; McCormick F; Marshall CJ
Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1629-33. PubMed ID: 3278322
[TBL] [Abstract][Full Text] [Related]
18. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
19. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
20. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
